Research Analysts Set Expectations for Korro Bio, Inc.’s Q3 2024 Earnings (NASDAQ:KRRO)

Korro Bio, Inc. (NASDAQ:KRRO) – HC Wainwright decreased their Q3 2024 earnings per share estimates for shares of Korro Bio in a research note issued to investors on Wednesday, August 14th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($2.40) per share for the quarter, down from their prior estimate of ($2.24). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.64) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.45) EPS, FY2024 earnings at ($9.72) EPS, Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($2.56) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.17) EPS.

Korro Bio (NASDAQ:KRRO) last announced its earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04).

Several other research analysts have also weighed in on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $120.00 price objective on shares of Korro Bio in a research report on Wednesday, May 15th. William Blair initiated coverage on Korro Bio in a research report on Wednesday. They issued an “outperform” rating and a $180.00 price objective for the company. Finally, Royal Bank of Canada lowered their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $135.00.

Korro Bio Stock Down 2.6 %

NASDAQ:KRRO opened at $43.91 on Friday. Korro Bio has a one year low of $9.15 and a one year high of $97.91. The stock has a 50 day moving average price of $41.10 and a 200 day moving average price of $53.05.

Institutional Investors Weigh In On Korro Bio

A number of institutional investors have recently added to or reduced their stakes in the business. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Korro Bio during the 4th quarter worth approximately $53,648,000. Eventide Asset Management LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $26,185,000. 72 Investment Holdings LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $13,269,000. Driehaus Capital Management LLC acquired a new position in shares of Korro Bio during the 2nd quarter worth approximately $3,958,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $4,352,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).